DGIdb - PACLITAXEL Drug Record

PACLITAXEL chembl:CHEMBL428647 ApprovedAntineoplasticImmunotherapy

Alternate Names:

NSC-125973
BMS-181339-01
TAXOL 100
ABRAXANE
DHP 107
NK 105
ABI-007
TAXOL
BMS 181339-01
QW-8184
MBT 0206
PACITAXEL
PAXENE
PACLITAXEL
INTAXEL
CAPXOL
MITOTAX
CYCLOPAX
GENEXOL
LIPOPAC
ANZATAX
ONXOL
TAXALBIN
GENETAXYL
TAXOL A
PLAXICEL
YEWTAXAN
5BETA,20-EPOXY-1,2-ALPHA,4,7BETA,10BETA,13ALPHA-HEXAHYDROXYTAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE
EBETAXEL
chembl:CHEMBL428647
drugbank:01229
rxcui:56946
chemidplus:33069-62-4
pubchem.compound:36314

Drug Info:

Year of Approval	1992
Drug Class	antineoplastic agents
Drug Indications	for treatment of peripheral arterial disease (PAD)
Drug Indications	antiinflammatory agent,DMARD
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(13 More Sources)

Publications:

Bio M et al., 2013, Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry., J Med Chem
Vine KL et al., 2007, An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins., J Med Chem
Asami Y et al., 2012, Protuboxepin A, a marine fungal metabolite, inducing metaphase arrest and chromosomal misalignment in tumor cells., Bioorg Med Chem
O'Boyle NM et al., 2014, β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand., J Med Chem
Sathish Kumar B et al., 2014, Synthesis of neolignans as microtubule stabilisers., Bioorg Med Chem
Zhao Y et al., 2013, Dual-functional abeo-taxane derivatives destabilizing microtubule equilibrium and inhibiting NF-κB activation., J Med Chem
Kamal A et al., 2014, Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors., Bioorg Med Chem Lett
Kumar AS et al., 2013, Design and synthesis of biaryl aryl stilbenes/ethylenes as antimicrotubule agents., Eur J Med Chem
Parrino B et al., 2015, Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action., Eur J Med Chem
Tu HY et al., 2009, Ursolic acid derivatives induce cell cycle arrest and apoptosis in NTUB1 cells associated with reactive oxygen species., Bioorg Med Chem
Kumar M et al., 2013, Tubulin inhibitors from an endophytic fungus isolated from Cedrus deodara., J Nat Prod
Rai et al., 2006, Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats., Exp. Biol. Med. (Maywood)
Sawers et al., 2014, Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines., Br. J. Cancer
Cheung et al., 2009, Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers., Mol. Cancer
Kovács et al., 2007, Effects of taxol treatment on the microtubular system and mitochondria of Tetrahymena., Cell Biol. Int.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Horwitz, 1992, Mechanism of action of taxol., Trends Pharmacol. Sci.
Qiu et al., 2005, Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death., Int. J. Oncol.
Zhang et al., 2004, [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro]., Zhonghua Fu Chan Ke Za Zhi
Gréen et al., 2006, mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy., Clin. Cancer Res.
Spletstoser JT et al., 2006, Single-site chemical modification at C10 of the baccatin III core of paclitaxel and Taxol C reduces P-glycoprotein interactions in bovine brain microvessel endothelial cells., Bioorg Med Chem Lett
Nanovskaya et al., 2005, Role of P-glycoprotein in transplacental transfer of methadone., Biochem. Pharmacol.
Ibrado et al., 1997, Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells., Cancer Res.
Qian J et al., 2012, Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment., Chest
Lee SY et al., 2014, Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy., Eur J Cancer
McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res
Gately et al., 1996, Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153., Br. J. Cancer
Ueno et al., 2006, Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin., Cancer Lett.
Brachova P et al., 2013, The consequence of oncomorphic TP53 mutations in ovarian cancer., Int J Mol Sci
Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
Medeiros et al., 2003, Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome., Int. J. Clin. Oncol.
Lu et al., 2002, The effect of paclitaxel on gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells., Food Chem. Toxicol.
Abraham JE et al., 2014, Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel., Clin Cancer Res
Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics
O'Brien et al., 2008, Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer., Cancer Res.
Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
Anbalagan et al., 2012, Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts., Mol. Cancer Ther.
Romero-Benitez et al., 2004, In vivo erythroid recovery following paclitaxel injury: correlation between GATA-1, c-MYB, NF-E2, Epo receptor expressions, and apoptosis., Toxicol. Appl. Pharmacol.
Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
Yoshino et al., 2006, Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy., Clin. Cancer Res.
Matsuyoshi et al., 2006, Bcl-2 phosphorylation has pathological significance in human breast cancer., Pathobiology
Gan et al., 2006, Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors., Pharm. Res.
Thomadaki et al., 2006, Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS., Biol. Chem.
Zhang et al., 2007, Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells., Int. J. Cancer
Vilmar et al., 2013, Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial., Ann. Oncol.
Harmsen et al., 2009, Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor., Cancer Chemother. Pharmacol.
Pereira D et al., 2016, Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile., Eur J Clin Pharmacol
Menendez et al., 2005, Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity., Int. J. Cancer
Foster et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol. Cancer Ther.
Thanapprapasr et al., 2015, PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer., Mol. Cancer Ther.
Hyman et al., 2015, Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors., Cancer Chemother. Pharmacol.
Boyle et al., 2001, The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin., Cancer Chemother. Pharmacol.
Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
Guarneri et al., 2015, Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer., Oncologist
Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.
Yu et al., 2015, Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092., PLoS ONE
Knuefermann et al., 2003, HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells., Oncogene
Mu et al., 2014, AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models., J. Exp. Clin. Cancer Res.
Satoh et al., 2014, Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study., J. Clin. Oncol.
Awada et al., 2016, Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial., JAMA Oncol
Jordan et al., 2016, HER2 expression identifies dynamic functional states within circulating breast cancer cells., Nature
Fader AN et al., 2018, Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu., J Clin Oncol
Yang et al., 2003, p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells., J. Clin. Endocrinol. Metab.
Hegde et al., 2013, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer., Sci Transl Med
Hu L et al., 2016, Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients., J Clin Pharmacol
Leskelä S et al., 2011, Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity., Pharmacogenomics J
García-Martín et al., 2006, Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8., Pharmacogenomics
Wilson et al., 2016, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma., Clin. Cancer Res.
Eberhard et al., 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib., J. Clin. Oncol.
Ratner et al., 2012, A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer., Oncogene
Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
Oizumi S et al., 2012, Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial., Oncologist
Han et al., 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung., J. Clin. Oncol.
Rosell et al., 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol.
Goto K et al., 2012, Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer., J Thorac Oncol
Zhou et al., 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol.
Maemondo et al., 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR., N. Engl. J. Med.
Mitsudomi et al., 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial., Lancet Oncol.
Mok et al., 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma., N. Engl. J. Med.
Xu et al., 2015, Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4., J. Proteome Res.
Goebel et al., 2006, Tubulin polymerization modulates interleukin-2 receptor signal transduction in human T cells., J. Recept. Signal Transduct. Res.
Marcath LA et al., 2019, Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure., Pharmacogenomics
Hui et al., 1998, Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes., Arthritis Rheum.
Mabuchi et al., 2002, Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel., J. Biol. Chem.
Bosó V et al., 2014, SNPs and taxane toxicity in breast cancer patients., Pharmacogenomics
Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol
Bang et al., 2015, Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer., J. Clin. Oncol.
Greenberg et al., 2005, Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism., Oncogene
Baldwin RM et al., 2012, A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101., Clin Cancer Res
Abaza et al., Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells., Tumour Biol.
Nakajima Y et al., 2006, Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer., Clin Pharmacol Ther
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Apellániz-Ruiz M et al., 2015, Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy., Clin Cancer Res
Westerlund et al., 1997, Ovarian cancer cell invasion is inhibited by paclitaxel., Clin. Exp. Metastasis
Bachmann HS et al., 2015, The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients., Br J Clin Pharmacol
Li et al., 2007, Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death., Cell Death Differ.
Stoeck et al., 2014, Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma., Cancer Discov
Park HS et al., 2016, Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy., Pharmacogenet Genomics
Mbatchi LC et al., 2015, Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination., Pharmacogenomics
Oguri et al., 2008, MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer., Mol. Cancer Ther.
Lee et al., 1997, Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter., Mol. Cell. Biol.
Yu et al., 2015, Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules., Cancer Cell
Boora GK et al., 2016, Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)., Cancer Med
Guo Q et al., 2015, Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--response., Clin Cancer Res
Apellániz-Ruiz M et al., 2015, Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--letter., Clin Cancer Res
Balko et al., 2016, Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence., Sci Transl Med
Sato Y et al., 2011, Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel., J Thorac Oncol
Russo et al., 2006, E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents., Cancer Res.
Takahashi et al., 2005, Cyclin A-associated kinase activity is needed for paclitaxel sensitivity., Mol. Cancer Ther.
Anand et al., 2003, AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol., Cancer Cell
Gandara et al., 2009, Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics., J. Clin. Oncol.
Santibáñez M et al., 2013, The MAD1 1673 G → A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer., Pharmacogenet Genomics
Werner et al., 2014, Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer., PLoS ONE

PACLITAXEL STMN1

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24587245

Sources:
CIViC
PACLITAXEL FGD4

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22843789

Sources:
PharmGKB
PACLITAXEL EIF4EBP1

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15897904

Sources:
NCI
PACLITAXEL PDCD4

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25928036

Sources:
CIViC
PACLITAXEL NFE2

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14761679

Sources:
NCI
PACLITAXEL SPATA5

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
PACLITAXEL EPHA5

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26763541 26133777 26133776 22843789

Sources:
PharmGKB
PACLITAXEL MAD1L1

Interaction Score: 0.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23407047

Sources:
PharmGKB
PACLITAXEL DSCAM

Interaction Score: 0.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21079520

Sources:
PharmGKB
PACLITAXEL MYB

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15001837

Sources:
NCI
PACLITAXEL TUBB4A

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC
PACLITAXEL TUBA3C

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC
PACLITAXEL TRIM5

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PACLITAXEL ABCC10

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18445659

Sources:
CIViC
PACLITAXEL TLE3

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
PACLITAXEL SOX10

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23963862

Sources:
PharmGKB
PACLITAXEL FNTB

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26033044

Sources:
PharmGKB
PACLITAXEL SOD2

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25495407

Sources:
PharmGKB
PACLITAXEL TUBB1

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name oral paclitaxel

Novel drug target Established target

Trial Name Abraxane

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901 19575780 17314054 17016423 17139284 1350385

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND
PACLITAXEL TUBB3

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Drug family Taxane

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ClearityFoundationBiomarkers ChemblInteractions CGI
PACLITAXEL ACSS2

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
PACLITAXEL PGP

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
PACLITAXEL TUBA1C

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBA3D

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBB6

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBA3E

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tubulin inhibitor

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBB2B

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBA4A

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tubulin inhibitor

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBB8

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBA1B

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBA1A

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBB2A

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBB4B

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions
PACLITAXEL TUBB

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Details of Interaction Mitotic cell cycle arrest in A431 cells

Endogenous Drug? False

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions GuideToPharmacology TTD
PACLITAXEL BCL2

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Abraxane

Novel drug target Established target

Trial Name AI-850

PMIDs:
23963862 17062688 17119350 16741658 16895478 17230521

Sources:
TdgClinicalTrial ClearityFoundationClinicalTrial TEND PharmGKB TTD
PACLITAXEL MAP3K1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
PACLITAXEL ERCC1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25495407 17229776

Sources:
CIViC PharmGKB
PACLITAXEL ERCC2

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19470925

Sources:
CIViC
PACLITAXEL FOS

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9588740

Sources:
NCI
PACLITAXEL GSTT1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12851839

Sources:
NCI
PACLITAXEL EDNRB

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16741060

Sources:
NCI
PACLITAXEL LIF

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11800022

Sources:
NCI
PACLITAXEL SLCO1B3

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26641474 26267044 21151855

Sources:
PharmGKB
PACLITAXEL SMAD4

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Imatinib + Carboplatin + Paclitaxel

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB
PACLITAXEL RRM1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23038758

Sources:
CIViC
PACLITAXEL SLC29A1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24361227

Sources:
PharmGKB
PACLITAXEL E2F1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16849574

Sources:
NCI
PACLITAXEL NOTCH1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MRK-003 + Paclitaxel

Indication/Tumor Type triple-receptor negative breast cancer

Response Type no benefit

PMIDs:
25104330

Sources:
JAX-CKB
PACLITAXEL CDKN1A

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12574211

Sources:
NCI
PACLITAXEL NAT2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11955677

Sources:
NCI
PACLITAXEL BIRC5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16211241 15347474

Sources:
ClearityFoundationBiomarkers NCI
PACLITAXEL CYP1B1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24599932 21151855

Sources:
PharmGKB
PACLITAXEL CASP7

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22441531

Sources:
PharmGKB
PACLITAXEL FASN

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15657900

Sources:
NCI
PACLITAXEL GSTM1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26803611

Sources:
PharmGKB
PACLITAXEL CDKN2A

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Imatinib + Carboplatin + Paclitaxel

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB
PACLITAXEL NRG1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23390248

Sources:
CIViC
PACLITAXEL ABCC3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18593940

Sources:
CIViC
PACLITAXEL RAF1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
PACLITAXEL DDIT3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8554977

Sources:
NCI
PACLITAXEL MMP2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9174131

Sources:
NCI
PACLITAXEL EGFR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sapitinib + Paclitaxel

Indication/Tumor Type inflammatory breast carcinoma

Response Type sensitive

PMIDs:
24886365 22581822 22370314 22285168 21900837 21783417 20573926 20022809 19692680 22139083

Sources:
JAX-CKB CIViC PharmGKB
PACLITAXEL IL2RA

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16595340

Sources:
NCI
PACLITAXEL SYK

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26096845

Sources:
CIViC
PACLITAXEL CASP3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9067280

Sources:
NCI
PACLITAXEL ERBB2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical - Pdx & cell culture

Indication/Tumor Type inflammatory breast carcinoma

combination therapy Sapitinib + Paclitaxel

PMIDs:
24886365 24868024 27078022 27556950 26432108 26469692 29584549

Sources:
JAX-CKB CIViC
PACLITAXEL PTEN

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical - Cell line xenograft

Indication/Tumor Type prostate adenocarcinoma

combination therapy XL147 + Paclitaxel

PMIDs:
25637314 25833835 25672916

Sources:
JAX-CKB CIViC
PACLITAXEL CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26179145 20212519 16753005

Sources:
NCI PharmGKB
PACLITAXEL PIK3CA

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Clinical Study

Response Type resistant

Indication/Tumor Type colorectal cancer

PMIDs:
21216929 26245675 24170767 26469692 12761490

Sources:
JAX-CKB NCI
PACLITAXEL KRAS

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type resistant

combination therapy Carboplatin + Erlotinib + Paclitaxel

Indication/Tumor Type non-small cell lung carcinoma

PMIDs:
26307133 21216929 16043828 22139083

Sources:
JAX-CKB CIViC
PACLITAXEL GSTP1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25010864

Sources:
CIViC
PACLITAXEL AURKA

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12559175

Sources:
CIViC
PACLITAXEL BRCA2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Carboplatin + Paclitaxel + Veliparib

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
PACLITAXEL ABCC1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
PACLITAXEL ABCC2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
PACLITAXEL SLCO1B1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30520341

Sources:
PharmGKB
PACLITAXEL ATM

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Olaparib + Paclitaxel

Indication/Tumor Type stomach cancer

Response Type predicted – sensitive

PMIDs:
26282658

Sources:
JAX-CKB
PACLITAXEL CXCL8

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9271387

Sources:
NCI
PACLITAXEL NR1I2

Interaction Score: 0.02

Interaction Types & Directionality:

agonist (activating)

inducer (activating)

Interaction Info:

Specific Action of the Ligand Agonist

Endogenous Drug? False

PMIDs:
18839173 21151855

Sources:
GuideToPharmacology PharmGKB
PACLITAXEL SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy KX2-391 + Paclitaxel

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
22784709

Sources:
JAX-CKB
PACLITAXEL ABCG2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
PACLITAXEL BDNF

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16778834

Sources:
NCI
PACLITAXEL BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Carboplatin + Paclitaxel + Veliparib

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
12684687

Sources:
JAX-CKB NCI
PACLITAXEL PDGFRA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Imatinib + Carboplatin + Paclitaxel

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB
PACLITAXEL CDK2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16020661

Sources:
NCI
PACLITAXEL CYP19A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PACLITAXEL JAK2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy NVP-BSK805 + paclitaxel

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
27075627

Sources:
JAX-CKB
PACLITAXEL MET

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type gastric adenocarcinoma

combination therapy Crizotinib + Trastuzumab + Paclitaxel

Evidence Type Actionable

PMIDs:
26432108 28514312

Sources:
JAX-CKB
PACLITAXEL ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16467099 16289636 15876424

Sources:
DTC NCI CIViC
PACLITAXEL PIK3CG

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12087097

Sources:
NCI
PACLITAXEL OPRM1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23963862

Sources:
PharmGKB
PACLITAXEL AKT1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ipatasertib + Paclitaxel

Indication/Tumor Type triple-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
PACLITAXEL TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MK-1775 + Carboplatin + Paclitaxel

Indication/Tumor Type ovarian cancer

Response Type sensitive

PMIDs:
16459017 24065105

Sources:
JAX-CKB NCI CIViC
PACLITAXEL TOP2A

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name liposomal encapsulated paclitaxel (LEP)

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
PACLITAXEL CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16890579 9187528 25398452 21151855

Sources:
PharmGKB
PACLITAXEL GMNN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PACLITAXEL AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: PACLITAXEL
- Version: 01-August-2011
Alternate Names:

PACLITAXEL Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1992

Publications:
TdgClinicalTrial: PACLITAXEL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: PACLITAXEL

Version: 14-September-2017

Alternate Names:

C1411 NCI drug code

Drug Info:

Publications:

Medeiros et al., 2003, Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome., Int. J. Clin. Oncol.

Nanovskaya et al., 2005, Role of P-glycoprotein in transplacental transfer of methadone., Biochem. Pharmacol.

Ibrado et al., 1997, Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells., Cancer Res.

DTC: PACLITAXEL

Version: 02-September-2020

Alternate Names:

CHEMBL428647 ChEMBL Drug ID

Drug Info:

Publications:

Bio M et al., 2013, Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry., J Med Chem

O'Boyle NM et al., 2014, β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand., J Med Chem

Parrino B et al., 2015, Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action., Eur J Med Chem

NCI: TAXOL

Version: 14-September-2017

Alternate Names:

C1411 NCI drug code

Drug Info:

Publications:

Gately et al., 1996, Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153., Br. J. Cancer

Abaza et al., Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells., Tumour Biol.

Yanagisawa et al., 2004, A novel interaction between kinesin and p120 modulates p120 localization and function., J. Biol. Chem.

JAX-CKB: Paclitaxel

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Yu et al., 2015, Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092., PLoS ONE

Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.

Guarneri et al., 2015, Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer., Oncologist

JAX-CKB: paclitaxel
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Balko et al., 2016, Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence., Sci Transl Med

PharmGKB: paclitaxel

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Lee SY et al., 2014, Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy., Eur J Cancer

Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res

Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics

CIViC: PACLITAXEL

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Brachova P et al., 2013, The consequence of oncomorphic TP53 mutations in ovarian cancer., Int J Mol Sci

Anand et al., 2003, AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol., Cancer Cell

Gréen et al., 2006, mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy., Clin. Cancer Res.

GuideToPharmacology: 135652721
- Version: 29-September-2020
Alternate Names:

PACLITAXEL GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Taxol
- Version: 2020.06.01
Alternate Names:

D0C4RB TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL428647
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: TAXOL
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: PACLITAXEL
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
CGI: Paclitaxel
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL428647
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: PACLITAXEL
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:

Trial Name	oral paclitaxel
Novel drug target	Established target
Trial Name	Abraxane

Mechanism of Interaction	Tubulin inhibitor
Direct Interaction	yes
Drug family	Taxane

Specific Action of the Ligand	Inhibition
Details of Interaction	Mitotic cell cycle arrest in A431 cells
Endogenous Drug?	False

combination therapy	Imatinib + Carboplatin + Paclitaxel
Indication/Tumor Type	melanoma
Response Type	sensitive

combination therapy	MRK-003 + Paclitaxel
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	no benefit

combination therapy	Sapitinib + Paclitaxel
Indication/Tumor Type	inflammatory breast carcinoma
Response Type	sensitive

Approval Status	Preclinical - Pdx & cell culture
Indication/Tumor Type	inflammatory breast carcinoma
combination therapy	Sapitinib + Paclitaxel

Approval Status	Preclinical - Cell line xenograft
Indication/Tumor Type	prostate adenocarcinoma
combination therapy	XL147 + Paclitaxel

Approval Status	Clinical Study
Response Type	resistant
Indication/Tumor Type	colorectal cancer

combination therapy	Carboplatin + Paclitaxel + Veliparib
Indication/Tumor Type	breast cancer
Response Type	predicted – sensitive

combination therapy	Olaparib + Paclitaxel
Indication/Tumor Type	stomach cancer
Response Type	predicted – sensitive

combination therapy	KX2-391 + Paclitaxel
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

combination therapy	NVP-BSK805 + paclitaxel
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

Indication/Tumor Type	gastric adenocarcinoma
combination therapy	Crizotinib + Trastuzumab + Paclitaxel
Evidence Type	Actionable

combination therapy	Ipatasertib + Paclitaxel
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	predicted – sensitive

combination therapy	MK-1775 + Carboplatin + Paclitaxel
Indication/Tumor Type	ovarian cancer
Response Type	sensitive

Trial Name	liposomal encapsulated paclitaxel (LEP)
Novel drug target	Established target

PACLITAXEL Drug Record

PACLITAXEL chembl:CHEMBL428647 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24587245

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22843789

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15897904

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25928036

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14761679

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26763541 26133777 26133776 22843789

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23407047

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21079520

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15001837

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18445659

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23963862

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26033044

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25495407

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name oral paclitaxel Novel drug target Established target Trial Name Abraxane

PMIDs: 23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901 19575780 17314054 17016423 17139284 1350385

Interaction Types & Directionality:

n/a

PMIDs:
24587245

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
22843789

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15897904

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25928036

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
14761679

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26763541 26133777 26133776 22843789

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23407047

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21079520

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15001837

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18445659

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

PMIDs:
23963862

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26033044

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25495407

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name oral paclitaxel

Novel drug target Established target

Trial Name Abraxane

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901 19575780 17314054 17016423 17139284 1350385

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Drug family Taxane

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ClearityFoundationBiomarkers ChemblInteractions CGI

Interaction Types & Directionality:

n/a

PMIDs:
21636554

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

PMIDs:
23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901

Sources:
DTC ChemblInteractions